TABLE 6.
Proportion of patients achieving PASI 75, PASI 90, and PASI 100 at week 4 and week 16 after secukinumab initiation for patients with complete and incomplete loading dose of secukinumab
| PASI improvement (%) | Week 4 (N = 94) | Week 16 (N = 62) | ||||
|---|---|---|---|---|---|---|
| Loading dose of secukinumab | Loading dose of secukinumab | |||||
| Complete (N = 45) | Incomplete (N = 49) | p‐value | Complete (N = 26) | Incomplete (N = 36) | p‐value | |
| n (%) (95% CI) | n (%) (95% CI) | n (%) (95% CI) | n (%) (95% CI) | |||
| PASI 75 | 23 (51.1%) | 11 (22.5%) | 24 (92.3%) | 22 (61.1%) | ||
| (36.5–65.7) | (10.8–34.1) | 0.004 † , * | (82.1–100.0) | (45.2–77.0) | 0.006 † , * | |
| PASI 90 | 15 (33.3%) | 5 (10.2%) | 22 (84.6%) | 20 (55.6%) | ||
| (19.6–47.1) | (1.7–18.7) | 0.006 † , * | (70.8–98.5) | (39.3–71.8) | 0.016 † , * | |
| PASI 100 | 5 (11.1%) | 3 (6.1%) | 19 (73.1%) | 17 (47.2%) | ||
| (1.9–20.3) | (0.0–12.8) | 0.473 ‡ | (56.0–90.1) | (30.9–63.5) | 0.042 † , * | |
*
p‐value <0.05, indicating a statistically significant difference.
†
Overall p‐value (2‐sided) based on Chi‐square test.
‡
Overall p‐value (2‐sided) based on Fisher's exact test.